Community experience of vemurafenib for BRAFV600 melanoma
Mené sur 3 226 patients atteints d'un mélanome métastatique présentant la mutation V600E du gène BRAF, cet essai international analyse les toxicités associées au vémurafenib
The final stage in the assessment of a new drug is its use in a community setting without the stringency of a clinical trial by investigators who do not necessarily have expertise in the treatment of patients with the drug. Selection of patients for treatment would be expected to be less strict and some complications might go undetected for longer periods, thereby increasing their severity in the community setting. The need for such a trial was particularly important for vemurafenib...
The Lancet Oncology , commentaire, 2013